Related Experiment Video
Updated: Jun 11, 2026
Merkel Cell Polyomavirus Infection and Detection
Published on: February 7, 2019
Characterization of monoclonal antibodies specific for the Merkel cell polyomavirus capsid
Diana V Pastrana1, Katherine A Pumphrey, Nicolas Cuburu
1Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892-4263, USA.
Abstract:
Merkel cell polyomavirus (MCV) has been implicated as a causative agent in Merkel cell carcinoma. Robust polyclonal antibody responses against MCV have been documented in human subjects, but monoclonal antibodies (mAbs) specific for the VP1 capsid protein have not yet been characterized. We generated 12 mAbs capable of binding recombinant MCV virus-like particles. The use of a short immunogenic priming schedule was important for production of the mAbs. Ten of the 12 mAbs were highly effective for immunofluorescent staining of cells expressing capsid proteins. An overlapping set of 10 mAbs were able to neutralize the infectivity of MCV-based reporter vectors, with 50% effective doses in the low picomolar range. Three mAbs interfered with the binding of MCV virus-like particles to cells. This panel of anti-capsid antibodies should provide a useful set of tools for the study of MCV.
Insights
Researchers developed 12 new monoclonal antibodies (mAbs) targeting Merkel cell polyomavirus (MCV) VP1 capsid protein. These MCV-specific mAbs neutralize viral infectivity and can be used as research tools.
Area of Science:
- Virology
- Immunology
- Oncology
Background:
- Merkel cell polyomavirus (MCV) is linked to Merkel cell carcinoma.
- Polyclonal antibody responses to MCV are known, but specific monoclonal antibodies (mAbs) against the VP1 capsid protein were uncharacterized.
Purpose of the Study:
- To generate and characterize monoclonal antibodies (mAbs) specific for the Merkel cell polyomavirus (MCV) VP1 capsid protein.
- To evaluate the utility of these mAbs in viral detection and neutralization.
Main Methods:
- Generation of 12 mAbs binding to recombinant MCV virus-like particles using a short immunogenic priming schedule.
- Assessment of mAb efficacy in immunofluorescent staining of MCV capsid protein-expressing cells.
- Evaluation of MCV neutralization activity and inhibition of virus-like particle binding to cells.
Main Results:
- Twelve mAbs were successfully generated, all binding to MCV virus-like particles.
- Ten mAbs demonstrated high efficacy in immunofluorescent staining.
- Ten mAbs neutralized MCV reporter vectors with low picomolar effective doses.
- Three mAbs inhibited MCV virus-like particle binding to cells.
Conclusions:
- A panel of 12 MCV-specific anti-capsid mAbs was developed.
- These mAbs exhibit potent neutralizing activity and can interfere with viral binding.
- The generated antibodies represent valuable tools for studying MCV infection and Merkel cell carcinoma.
More Related Videos
08:09Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope
Published on: March 24, 2017
11:10Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
Published on: June 29, 2016
